ClinicalTrials.gg

Mesothelioma, Malignant clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 340 studies for Mesothelioma, Malignant across more than 10 countries. 63 are recruiting or about to start. 247 of them are mainly about Mesothelioma, Malignant (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

Status

Completed
161
Recruiting
54
Terminated
41
Status unknown
33
Active, not recruiting
25
Withdrawn
14

Phase

Phase 2
172
Phase 1
128
Phase 3
18
Early Phase 1
2
Phase 4
1

Where

United States
165
Italy
45
United Kingdom
41
France
29
Netherlands
22
Belgium
20

Who develops what

Add Mesothelioma, Malignant to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 6 programs from 6 companies, 3 with this as their studies’ main aim; 1 with a live phase 3 study; 1 primary completion in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
NivolumabRecent, repeated
Evidence
  • NCT06362369 · 7 Hills Pharma, LLC · Phase 2 · live · background · “Nivolumab” · registered Mar 2024
  • NCT06097728 · AstraZeneca · Phase 3 · live · comparator · “Nivolumab” · registered Oct 2023
  • NCT04665206 · Vivace Therapeutics, Inc · Phase 2 · live · background · “Nivolumab & Ipilimumab” · registered Dec 2020
  • NCT04013334 · Momotaro-Gene Inc. · Phase 2 · background · “Nivolumab Injection [Opdivo]” · registered May 2019
Bristol-Myers Squibb76% of its industry studiesUS: Bristol-Myers Squibb (FDA 2014)EU: Bristol-Myers Squibb (EMA 2015)22 studies
IpilimumabRecent, repeated
Evidence
  • NCT06362369 · 7 Hills Pharma, LLC · Phase 2 · live · background · “Ipilimumab” · registered Mar 2024
  • NCT06097728 · AstraZeneca · Phase 3 · live · comparator · “Ipilimumab” · registered Oct 2023
  • NCT04665206 · Vivace Therapeutics, Inc · Phase 2 · live · background · “Nivolumab & Ipilimumab” · registered Dec 2020
Bristol-Myers Squibb91% of its industry studiesUS: Bristol-Myers Squibb (FDA 2011)EU: Bristol-Myers Squibb (EMA 2011)22 studies
fludarabineRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07510815 · Beijing Biotech · Phase 2 · live · background · “Fludarabine” · registered Mar 2026
  • NCT05451849 · TCR2 Therapeutics · Phase 2 · background · “Fludarabine” · registered Jun 2022
  • NCT03907852 · TCR2 Therapeutics · Phase 2 · live · background · “fludarabine” · registered Apr 2019
Beijing Biotech18% of its industry studies22 studies
CyclophosphamideRecent, repeated
Evidence
  • NCT07510815 · Beijing Biotech · Phase 2 · live · background · “Cyclophosphamide” · registered Mar 2026
  • NCT05451849 · TCR2 Therapeutics · Phase 2 · background · “Cyclophosphamide” · registered Jun 2022
  • NCT03907852 · TCR2 Therapeutics · Phase 2 · live · background · “cyclophosphamide” · registered Apr 2019
Hoffmann-La Roche13% of its industry studiesUS: off-patent, 12 generics marketed22 studies

6 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
TEAD Inhibitor VT3989☆ Track1 live phase-3 study: NCT07824986Vivace Therapeutics, Inc

The 1 in phase 3 with the nearest primary completion, of 6 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 14 Mar 2027 est.EB-MF-CAR-NK-01 · Beijing Biotech · Phase 2 main aimstudied with fludarabinestudied with CyclophosphamideNCT07510815 Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma — primary endpoint: Incidence of dose-limiting toxicities (DLTs) after first CAR-NK infusion · 36 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Mesothelioma, Malignant studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Immune checkpoint inhibitors 14 open · Tyrosine kinase inhibitors (TKIs) 3 open · Antimetabolites 2 open · PARP inhibitors 1 open · Angiogenesis inhibitors 6

Coming up

19studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 54 Mesothelioma, Malignant studies recruiting now, 42 (78%) set no upper age limit and 5 (9%) stop at 75 or younger. 2 (4%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 3 (6%) take healthy volunteers.

Recruiting studies that take each age, of 54
AgeWomenMen
102 (4%)2 (4%)
1853 (98%)53 (98%)
3054 (100%)54 (100%)
4054 (100%)54 (100%)
5054 (100%)54 (100%)
6554 (100%)54 (100%)
7553 (98%)53 (98%)
8547 (87%)47 (87%)

Across all 340 studies, recruiting or not: 8% stop at 75 or younger and 2% at 65; 8% take children; 1% are for women only and <1% for men only; 2% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Mesothelioma, Malignant studies take

Of 48 phase 2 interventional studies under Mesothelioma, Malignant, half reached primary completion within 48 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 163 mo39–89 · 40 studies——
Phase 1/271 mo43–85 · 31 studies——
Phase 248 mo29–87 · 48 studies—67 mo27–100 · 41 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 340. Browse all 340 → or search them.